For the first time in more than two decades, the Illinois men’s basketball team will still be dancing when the Final Four tips off.

Iowa’s underdog run in the NCAA Tournament ended Saturday with a 71-59 loss to a dominant Illinois team. Before Illinois could cut down the nets at Houston’s Toyota Center, a buzzer malfunction caused a loud, roughly 10-minute delay.

The buzzer initially sounded signaling the end of a media timeout with just under eight minutes remaining in the first half. The horn continued blaring for about another seven minutes.

CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM

Players stood on the court ready to play for a couple of minutes before both teams started to warm up as the buzzer continued to sound.

It was finally silenced, to cheers from the crowd, but then the main scoreboard and video screen that hangs over the middle of the court went dark.

The game ultimately resumed with the big scoreboard still off. Two smaller scoreboards at each end of the arena were working.

Freshman guard Keaton Wagler scored 25 points to help secure Illinois’ first Final Four berth since 2005.

This will be the sixth overall trip to the Final Four for Illinois, which has never won a national title. The Fighting Illini will face either Duke or UConn next week in Indianapolis.

The Associated Press contributed to this report.

Follow Fox News Digital’s sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.

Outspoken ESPN star Stephen A. Smith took a clear position in the ongoing debate about transgender athletes’ participation in girls and women’s sports.

“Biological men should not be competing against biological girls in sports, period,” Smith said during an appearance on “Real Time with Bill Maher” after the Olympics’ policy on transgender women was mentioned.

“What about protecting the young ladies? Young ladies going up against biological men — biological men — there is no excuse for that.”

CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM

Smith then mentioned former University of Pennsylvania swimmer Lia Thomas.

OLYMPIANS REACT TO THE IOC’S POLICY CHANGE TO PROTECT WOMEN’S SPORTS

“Lia Thomas, for example, was a male, and he was ranked over 400th in the world. … And then he became a she. … And No. 1. Well … does it really take an Einstein to realize that there’s something wrong with that picture?”

Smith has previously spoken about his views on transgender athletes in girls and women’s sports, including during a February 2025 Radio Row interview ahead of that year’s Super Bowl.

“So, that’s how I look at it. LGBTQ rights and all that stuff, I’m in full support of that, but when transgender athletes — men — are transitioning to women and they’re competing in female sports, that’s a different animal to me,” he said.

“That’s not just about LGBTQ rights. That’s about preying on the rights of females out there everywhere who were born female, and they’re at a decided disadvantage.”

Those comments from Smith surfaced around the same time in 2025 when President Donald Trump signed the “Keeping Men Out of Women’s Sports” executive order, which directed federal agencies to interpret Title IX based on biological sex at birth.

The NCAA complied with Trump’s executive order and changed its policy.

Fox News’ Ryan Gaydos contributed to this report.

Follow Fox News Digital’s sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.

For women struggling with weight gain after menopause, a new study suggests that adding hormone therapy to a popular obesity drug may lead to greater weight loss.

Postmenopausal women lost about 35% more weight when using menopausal hormone therapy alongside tirzepatide — a GLP-1-based, Food and Drug Administration-approved drug for overweight and obesity — compared to those taking the drug alone, according to a Mayo Clinic study.

The findings, published in February in The Lancet Obstetrics, Gynaecology, & Women’s Health, highlight a possible new strategy for addressing weight gain after menopause, when hormonal shifts can increase the risk of obesity, cardiovascular disease and type 2 diabetes.

STOPPING OZEMPIC? NEW STUDY REVEALS SURPRISING WEIGHT REGAIN RESULTS AFTER GLP-1S

“This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women,” Dr. Regina Castaneda, the study’s first author, said in a statement. 

Researchers analyzed 120 postmenopausal women with overweight or obesity who took tirzepatide for at least 12 months, including 40 who also used hormone therapy and 80 who did not.

Hormone therapy is commonly used to treat menopause symptoms like hot flashes and night sweats, while tirzepatide helps regulate appetite and blood sugar.

WEIGHT-LOSS MEDICATIONS COULD IMPACT SEXUAL HEALTH IN UNEXPECTED WAYS

Women in the hormone therapy group lost an average of 19.2% of their body weight, compared to 14.0% in the non-hormone group — about 35% greater relative weight loss — with more women reaching significant weight-loss thresholds, according to the study.

Despite the results, researchers emphasized that the study was observational and cannot prove cause and effect.

“Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” said Dr. Maria Daniela Hurtado Andrade, an endocrinologist at Mayo Clinic and senior author of the study.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Outside experts agree that the findings must be interpreted cautiously.

“As with all observational studies, we need to interpret this study with a grain of salt,” Dr. Gillian Goddard, a board-certified endocrinologist, told Fox News Digital. 

Goddard, who is also an adjunct assistant professor of medicine at the NYU Grossman School of Medicine, noted that the findings show a link, but do not prove that hormone therapy, which usually includes estrogen, directly caused the additional weight loss.

CLICK HERE FOR MORE HEALTH STORIES

“There may be important differences between the two groups,” she added. “For one thing, the group taking estrogen may be healthier than the groups that didn’t take estrogen … Healthier people are more likely to eat a healthy diet and exercise in addition to taking tirzepatide. That could lead to more weight loss.” 

Symptom relief from the therapy may have also improved sleep and well-being, making it easier for the group to maintain diet and exercise routines, Hurtado Andrade noted.

Researchers also pointed to a possible biological explanation. Preclinical data suggest estrogen may enhance the appetite-suppressing effects of GLP-1-based medications like tirzepatide, according to the study.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Goddard said that theory is plausible but unproven.

“The other possibility is that estrogen interacts with tirzepatide in some way that makes it more potent,” she said, adding, “We will need randomized studies to get a better handle on that.”

As for safety, experts say using the two together appears safe for most women. However, hormone therapy is not recommended for all patients, especially those with a history of certain cancers, blood clots or other underlying health risks, according to the Mayo Clinic.

Researchers say future randomized trials will aim to confirm the findings and explore whether the combination also improves broader cardiometabolic health outcomes, according to the study.

“If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage,” said Hurtado Andrade.

Fox News Digital has reached out to the study authors for comment.